Objective: It has been shown previously that the internal mammary artery releases more cyclic guanosine monophosphate after stimulation with atrial natriuretic peptide than the saphenous vein, and that C-type natriuretic peptide possesses a cyclic guanosine monophosphate stimulating potential on saphenous vein bypass grafts. The present study was undertaken to investigate intracellular content and extracellular release of cyclic guanosine monophosphate, by the internal mammary artery and saphenous vein, after challenge with further members of the natriuretic peptide family. Methods: Specimens of human internal mammary artery and saphenous vein from 29 patients were cut into segments and stimulated with 10 26 M concentrations of atrial natriuretic peptide (internal mammary artery n 8, saphenous vein n 10), brain natriuretic peptide (internal mammary artery n 9, saphenous vein n 13), C-type natriuretic peptide (internal mammary artery n 12, saphenous vein n 15), and urodilatin (internal mammary artery n 8, saphenous vein n 12). Intracellular content and extracellular release of cyclic guanosine monophosphate were determined using an 125 I radioimmunoassay. Results: The following median stimulated intracellular cyclic guanosine monophosphate concentrations were measured in the internal mammary artery and saphenous vein: 35358 and 8672 fmol/cm 2 (P , 0:001) after atrial natriuretic peptide, 45632 and 7830 fmol/cm 2 (P 0:003) after brain natriuretic peptide, 10144 and 13216 fmol/cm 2 (P NS for intergraft comparison) after C-type natriuretic peptide, and 20949 and 6690 fmol/cm 2 (P 0:001) after urodilatin. Stimulation with atrial natriuretic peptide, brain natriuretic peptide and urodilation also led to a signi®cant increase of extracellular cyclic guanosine monophosphate release by the internal mammary artery. Conclusion: We conclude that brain natriuretic peptide and urodilatin exhibit a similarly effective cyclic guanosine monophosphate-stimulating potential on the internal mammary artery as atrial natriuretic peptide. In contrast, C-type natriuretic peptide shows comparable effects on the internal mammary artery and saphenous vein. q
Introduction
Vasospasm, local thrombosis, and development of neointimal hyperplasia, as well as atherosclerotic lesions, are the main problems jeopardizing a coronary artery bypass graft [1] . Different protecting systems such as the nitric oxide [2] and prostacyclin pathways [3] , which exhibit vasodilating and platelet inhibiting actions seem to provide local resistance against these events. Natriuretic peptides due to vasodilating and antiproliferative properties, might provide protective action for coronary artery bypass grafts as well [4±7] . Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are the main representatives of the natriuretic peptide family.
Their effects are mediated via cyclic guanosine monophosphate (cGMP), which is generated by the intrinsic guanylyl cyclase activity of the type A and type B natriuretic peptide receptor.
We have recently been able to demonstrate superior cGMP production by the internal mammary artery in reponse to ANP, as compared to the right gastroepiploic artery and the saphenous vein [7] . It has been shown by others that the two members of the natriuretic peptide family, ANP and CNP, seem to have different effects on cGMP production in human coronary artery bypass grafts [5, 6] . The aim of the present study was to further investigate these variations in cGMP release and to assess the reactions of the internal mammary artery and saphenous vein to stimulation by BNP and the stable natriuretic peptide urodilatin, a substance that could potentially be applied in the clinical setting [8] .
Material and methods

Specimens
The study protocol received approval from the Institutional Review Board and written informed consent was obtained from all patients studied. Remnants of IMA and SV were obtained from 29 patients undergoing CABG procedures and transported to the laboratory in HEPES± RPMI 1640 medium (Sigma Aldrich Co. Ltd, UK) at room temperature. Adherent tissue was carefully dissected from the vessel, which was opened longitudinally in order to expose the endothelium. The vessels were then cut into segments, one for control measurements and the others for stimulation with different natriuretic peptides. The number of specimens investigated are shown in Figs. 1±4. From the majority of patients both internal mammary artery and saphenous vein were obtained. In several cases, however, due to inadequate length of internal mammary artery only saphenous vein could be taken for investigation. Control vessels and corresponding stimulated vessels were always obtained from the same patient.
Small tubes were ®lled with 450 ml of HEPES±RPMI 1640 medium containing 0.7426 mmol/l of the phosphordiesterase-inhibitor 3-isobutyl-1-methyl-xanthine (IBMX) and 50 ml of ANP (9128, Peninsula, St. Helens, UK), BNP (H 9060, Bachem, Bubendorf, Switzerland), CNP (9030, Peninsula, St. Helens, UK) and Urodilatin (H 3046, Bachem, Bubendorf, Switzerland), respectively. The natriuretic peptide concentration thus was 10 26 M. The intact vascular segments were placed in the solution and incubated for 10 min at 378C with 5% CO 2 and 95% air. Control vessels remained unstimulated in 500 ml HEPES± RPMI 1640 medium. Aliquots were taken from the supernatants and stored at 2208C, until determination of cGMP. For measurement of intracellular cGMP, the IMA and SV pieces were shock frozen in liquid nitrogen and stored at 2808C. They were homogenized in liquid nitrogen and solved in 1 ml of 0.01 M HCl for douncing. After centrifugation at 2200 £ g for 15 min at 48C, the supernatant was stored in aliquots at 2208C.
Determination of cGMP
Cyclic GMP release was measured in the supernatants using an 125 I Biotrak Amersham RIA (Amersham International, Buckinghamshire, UK). Aliquots were thawed and acetylated with a solution of acetic anhydride and triethylamine. They were then incubated for 24 h with a ®xed quantity of antiserum and a ®xed quantity of 125 I marked cGMP at 48C. The antibody-bound cGMP was then reacted with the Amerlex-Me second antibody reagent, which contains second antibody that is bound to magnetizable polymer particles. The antibody-bound fraction was magnetically separated and then analyzed by a gamma counter. The concentration of unlabelled cGMP in the sample was determined by interpolation from a standard curve.
Statistical analysis
Statistical analysis was performed on the SPSS for Windows statistical software package. Results are expressed as median plus range. Stimulated vs. control values were compared with the non-parametric Wilcoxon-test for two related samples, comparisons between internal mammary artery and saphenous vein were carried out using the nonparametric Mann±Whitney U-test.
Fig. 2. After stimulation with 10
26 M BNP solution, there was a signi®cant increase of intracellular cGMP-production in the IMA (** P , 0:01 vs. control), whereas the response of the saphenous vein was not signi®cant. Stimulated intracellular cGMP levels were signi®cantly more pronounced in the internal mammary artery than in the saphenous vein ( ## P , 0:01 IMA vs. SV). BNP, brain natriuretic peptide; cGMP, cylic guanosine monophosphate; IMA, internal mammary artery; SV, saphenous vein.
Fig. 3. 10
26 M CNP solution elevated intracellular cGMP in both the IMA and the saphenous vein (** P , 0:01 vs. control) with a trend toward higher values in the saphenous vein. CNP, C-type natriuretic peptide; cGMP, cylic guanosine monophosphate; IMA, internal mammary artery; SV, saphenous vein.
Results
Intracellular cGMP content
There were no statistical differences between internal mammary artery and saphenous vein concerning control levels of intracellular cGMP. ANP led to a more pronounced cGMP stimulating effect in the IMA as compared with the SV (Fig. 1) . ANP induced intracellular cGMP concentrations were 35 358 (16 582±81 096) fmol/cm 2 and 8672 (3184±19 318) fmol/cm 2 , respectively (P , 0:001). BNP also showed a more pronounced cGMP increasing effect on the IMA than on the SV (Fig. 2) . Stimulated concentrations reached 45 632 (3851±127 223) fmol/cm 2 and 7830 (75±40 740) fmol/cm 2 (P 0:003). Intracellular cGMP content after CNP incubation was signi®cantly increased in both internal mammary artery and saphenous vein and amounted to 10 144 (611±44 545) fmol/cm 2 and 13 216 (1220±52 989) fmol/cm 2 , respectively (P NS for intergraft comparison) (Fig. 3) . Urodilatin was more effective on the IMA than on the SV (Fig. 4) . Intracellular cGMP concentrations after incubation with urodilatin were 20 949 (17 648±95 352) fmol/cm 2 and 6690 (309±17 325) fmol/cm 2 (P 0:001). 
Extracellular cGMP release
Baseline extracellular cGMP release was signi®cantly higher in IMA vs. SV and showed lower absolute values than intracellular content (Table 1) . ANP, BNP, and urodilatin signi®cantly stimulated cGMP release in both internal mammary artery and the saphenous vein, but effects were more pronounced in the former vessel. The in¯uence of CNP on the IMA was considerably less accentuated than the in¯uence of ANP, BNP, and urodilatin. ANP, BNP and CNP were able to signi®cantly increase the extracellular cGMP release from the saphenous vein.
Discussion
The natriuretic peptide family
Atrial natriuretic peptide and brain natriuretic peptide are produced in atrial and ventricular cardiac myocytes, respectively and predominantely exhibit diuretic, natriuretic, and vasorelaxant actions [9, 10] . C-type natriuretic peptide is distinct from A-and B-type natriuretic peptides in both structure and function. It is abundantly produced in the brain, where it acts as a neurotransmitter [11] . Another site of production is the vascular endothelium, and as a local mediator CNP shows vasodilating properties. A potent antigrowth effect has been demonstrated on cultured smooth muscle cells [12] and on neointima formation in a carotid artery injury model [13] . Due to the local vascular actions of CNP, the term`vascular natriuretic peptide' has been created [14] .
Urodilatin was ®rst puri®ed by Schulz±Knappe and Forssmann [15] , and is produced in the kidney where it causes natriuresis and diuresis in a paracrine fashion. Urodilatin exhibits an N-terminal extension of four amino acids in comparison to circulating ANP. This additional amino acid sequence seems to be responsible for the high resistance of urodilatin to enzymatic degradation by the neutral endopeptidase (NEP). Due to its biochemical stability the substance has already been used as a diuretic and natriuretic substance in clinical studies during the post-operative phase in heart and liver transplantation [8] .
Vascular effects of natriuretic peptides
In general, natriuretic peptides seem to counteract actions of the renin±angiotensin±aldosterone system and the endothelin system, which both cause vasoconstriction and promote vascular growth [16] . ANP and BNP predominantly bind to the guanylyl cyclase receptor type A, and can thereby effectively stimulate the release of cyclic guanosine monophosphate. The cGMP generated by guanylyl cyclase receptors leads to the relaxation of vascular smooth muscle [17] .
Natriuretic peptides in coronary artery disease and coronary artery surgery
What is the importance of the natriuretic peptide system in coronary artery disease and coronary artery surgery? Both ANP and BNP are known to increase coronary blood¯ow [18] . A study by Honkonen [19] has shown that especially signi®cant stenosis of the right coronary artery leads to high levels of ANP. Elevated plasma levels of ANP can be detected during the course of coronary artery bypass grafting (CABG) procedures [20] , an important fact regarding potential intra-operative protection of coronary artery bypass conduits. Nevertheless, CABG seems to have a less pronounced ANP stimulating action than valve replacement [21] .
Natriuretic peptide effects on coronary bypass grafts
It is well known that ANP and BNP show more predominant actions on arteries than on veins. A vasodilating effect of ANP on several human arteries was demonstrated by Hughes [22] , whereas a vasodilating effect was absent in human saphenous vein. These ®ndings are well in accordance with results of a study by Aardal, who demonstrated vasodilating properties of ANP on human internal mammary artery specimens in comparison to saphenous vein [4] . A stronger release of the vasodilating second messenger cGMP by the IMA in comparison to the SV was shown in by Zhang [6] and by our research group [7] . Vasodilating properties of BNP on endothelin-1 and phenylephrine precontracted pieces of IMA were demonstrated by Protter and coworkers [23] .
In our experiments, we have used micromolar natriuretic peptide concentrations, a level at which others have also found a signi®cant effect on coronary artery bypass grafts [4, 5] . Concerning the clinical relevance of our ®ndings, we would like to note that nanomolar concentrations of ANP have been demonstrated for the post-cardiopulmonary bypass period, and in a variety of cardiac dysfunctions [4, 24] .
One interesting ®nding in our study is that there seem to be no clear differences in baseline intracellular cGMP content of the internal mammary artery and saphenous vein. Ikeda and Itoh [5] also showed that endothelially denuded and homogenized samples of these two coronary bypass grafts showed about the same baseline content of cyclic GMP. Baseline cGMP release into the medium in our experiments was three to four times higher in the internal mammary artery. This con®rms the results of our previous studies [7] , which revealed higher basal extracellular release of cGMP by the internal mammary artery as compared with both the saphenous vein and right gastroepiploic artery. Whether the IMA is supplied with a more effective cGMP transport system into the extracellular space has, to our knowledge, not been investigated.
Effects of different members of the natriuretic peptide family 4.5.1. ANP, BNP
Our study revealed that ANP and BNP show about the same cGMP stimulating pattern on the internal mammary artery and on the saphenous vein. Both natriuretic peptides stimulated intra-and extracellular cGMP production signi®-cantly more pronounced in the internal mammary artery. Concerning ANP this is well in accordance with our previous ®ndings [7] .
CNP
In contrast to the marked and comparable effects of ANP, BNP, and urodilatin on the IMA and SV, CNP in our study showed only weak cGMP-stimulating action on the internal mammary artery. Similar intracellular levels of cyclic guanosine monophosphate after CNP application were found in the internal mammary artery and saphenous vein. This phenomenon has already been described: Ikeda and coworkers found that CNP, in comparison to ANP, increases the cGMP content of human saphenous vein and internal mammary artery to about the same extent [5] . They provided further explanations for this fact by showing that in the internal mammary artery, signi®cantly more natriuretic peptide receptor type A (NPR-A) gene transcript can be identi®ed than in the saphenous vein. Natriuretic peptide receptor type B (NPR-B) gene transcript, however, was detectable in saphenous vein specimen. Since NPR-B is the main receptor for CNP, this might be another explanation why CNP can stimulate cGMP production in the saphenous vein to a higher extent than other natriuretic peptides. Our results concerning CNP actions on IMA and SV are also well in accordance with ®ndings on isolated canine vessels, which clearly revealed that CNP seems to be a more potent venodilator than ANP [25] .
Urodilatin
To our knowledge, no data on the action of urodilatin on coronary artery bypass grafts has been published so far. As our results show, urodilatin seems to stimulate cGMP production by coronary bypass grafts to a similar extent as ANP and BNP, a fact which might be important if natriuretic peptides are considered as potential therapeutic agents. The excellent tolerance in clinical studies during the posttransplant period [8] speaks for functional and clinical testing of urodilatin.
Conclusions
According to the ®ndings in this study no clear differences between internal mammary artery and the saphenous vein can be found concerning baseline intracellular content of cyclic guanosine monophosphate. Extracellular cGMP release, however, seems to be more pronounced in the internal mammary artery than in the saphenous vein. ANP, BNP, and urodilatin are able to stimulate intracellular cGMP production and extracellular release of cGMP in both the IMA and the SV but effects on the IMA are much more pronounced. C-type or vascular natriuretic peptide exhibits less pronounced effects on the internal mammary artery and saphenous vein than cardial and renal natriuretic peptides. The cGMP stimulating effect on both coronary bypass grafts is comparable. Urodilatin, as a stable, clinically well tolerated natriuretic peptide, has a potential as a therapeutic agent.
